Feature Image

Life Science Leader: Cannabis-Based Pharmaceuticals: The Next Frontier?

Posted on

KannaLife Sciences was mentioned in an article by Life Science Leader written by Cliff Mintz about the companies cannabis-based pharmaceutical products and how it could be the next frontier of medical products.

Unlike medical marijuana companies, biopharmaceutical companies, including GW Pharma, Kannalife Sciences, Aphios, and others, are committed to developing cannabis-derived pharmaceuticals using conventional U.S. FDA regulatory approval pathways. “The idea behind our approach is to offer the market, and more importantly patients, a medicine that has been through a full regulatory review and is well characterized regarding efficacy, safety, and interactions with other drugs,” offered GW Pharma’s Schultz. He added, “None of those things are present in medical marijuana offerings.

View full size PDF in new window

View Original Article